Prosthesis for the treatment of focal epilepsy


To conduct a human safety trial for a new focal epilepsy therapy

Anticipated Impact: 

A novel and safe therapy for focal epilepsy patients who have no satisfactory alternative


Epilepsy can successfully be treated with drugs in only about 60% of patients. The remainder, particularly with focal non-convulsive seizures, can only be treated with removal of the affected area of the brain, which itself is only effective about half the time. Removing the affected area of the brain can also remove a critical area that leaves the patient disabled. An observation that cooling the affected area of the brain prevents seizures during neurosurgery will be exploited with a prosthesis that, if effective, would be safe and inexpensive. In a small human safety trial, a titanium prosthesis will be placed over the affected area of the brain to test whether sufficient cooling can occur. Therma Neurosciences, a startup company, is the commercialization partner.

Collaborating organization: Therma Neurosciences, Inc.

A supplement was awarded to switch from a passive to an active cooling method, which will be designed and implemented in the human trial.  This will result in more relevant data being collected and will accelerate commercialization.

Epilepsy Management

Grant Update

Principal Investigator:
Raimondo D'Ambrosio
Grantee Organization:
University of Washington
Grant Title:
Prosthesis for the treatment of focal epilepsy
Grant Cohort and Year:
2015 Proof of Concept (03)
Grant Period:
04/01/2015 - 03/31/2018 (Active)
Grant Amount:
The work is ongoing as planned.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact

Legislative Districts:
11, 34, 36, 37, 43, 46

Health Impacts

Epilepsy Management